Colombia’s Glivec Pricing Means “Worst Of Scenarios” For Pharma Industry
Executive Summary
AFIDRO, the association representing Colombia’s research-based pharmaceutical industry, is taking the government to court over new pricing regulations that follow the controversial declaration of public interest for Novartis’ Glivec (imatinib).
You may also be interested in...
Colombian Crack Down On Compulsory Licensing Under Attack
Civil society groups are calling for Colombian authorities to repeal a controversial decree that they say will make compulsory licensing harder and which would prevent declarations of public interest from being used to lower drug prices.
Novartis Takes On Colombia Over Glivec Pricing
Novartis is taking Colombian authorities to court over moves to cut the price of its anticancer Glivec (imatinib) and warns that the intellectual property rights of other products are under threat. Companies selling hepatitis C drugs should pay attention as their products could be next to face similar measures.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.